WO2003059949A2 - A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector - Google Patents
A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector Download PDFInfo
- Publication number
- WO2003059949A2 WO2003059949A2 PCT/IB2003/000116 IB0300116W WO03059949A2 WO 2003059949 A2 WO2003059949 A2 WO 2003059949A2 IB 0300116 W IB0300116 W IB 0300116W WO 03059949 A2 WO03059949 A2 WO 03059949A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- cxcr3
- cdna
- complexes
- sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 21
- 239000013604 expression vector Substances 0.000 title claims abstract description 9
- 230000033115 angiogenesis Effects 0.000 title claims description 5
- 230000005764 inhibitory process Effects 0.000 title description 4
- 230000004614 tumor growth Effects 0.000 title description 4
- 239000002299 complementary DNA Substances 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000206602 Eukaryota Species 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000004869 vascular alteration Effects 0.000 claims 1
- 208000011733 vascular alteration Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 10
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000000964 angiostatic effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention refers to a protein [SEQ. ID. N° 1], its use in diagnosis and therapy of tumours, and its cDNA [SEQ. ID. N° 2].
- SEQ. ID. N° 1 a protein [SEQ. ID. N° 1]
- SEQ. ID. N° 2 a cDNA
- CXCR3 mediates the angiostatic and anti tumour effects of chemokines IP-10, Mig and l-TAC and it is also known that, depending on the cell type expressing it, it can mediate completely different effects (chemotaxis, proliferation, adhesion, inhibition of proliferation).
- Fig.1 shows the sequence of the protein according to the invention.
- Fig.2 shows the sequence of the DNA expressing the protein of Fig. 1.
- Fig.3 shows schematically an expressing vector containing the cDNA sequence coding for CXCR3-B.
- CXCR3-B a new protein
- SEQ: 1 mediates the inhibition of endothelial cell growth induced by angiostatic chemokines IP-10, Mig, l-TAC and PF-4 and probably controls tumour growth.
- the present invention is related to the complexes containing the above said protein and the expression vectors and the plasmides containing such complexes.
- this new variant was confirmed by rapid amplification of cDNA ends performed on the total RNA of human thymus and endothelial tissue.
- the expression of the new mRNA of CXCR3 was identified in various human tissues as heart, skeletal muscle, kidney and liver.
- an expressing vector of the type usually employed for the transcription of recombinant molecules or for creating transient or stabile transfectants.
- An expressing vector according to the invention is, for example, a plasmide containing a promoter and a polyadenilation sequence (normally of viral origin) and a resistance to antibiotics for prokaryotes and/or eucaryotes (see Fig. 3).
- An immortalised cell line of human capillary endothelial cells was transfected with the expressing vector coding for CXCR3-B, an other vector codifying for the known CXCR3 protein (CXCR3-A) and respectively the two vectors deprived of the portion coding for the two proteins.
- Stable transfectants were obtained by selecting the cells with antibiotics G-418 and hygromicine and in such transfectants the expression of the two types of CXCR3 was examined by using flux cytofluorimetry in the presence of two types of monoclonal antibodies anti-CXCR3.
- CXCR3-B The newly identified receptor (CXCR3-B) is capable of binding all the three chemokines specific for CXCR3 (IP-10, Mig and l-TAC) which can induce inhibition of angiogenesis with various affinity while it can not bind other 17 different and not related chemokines.
- the transfectants of CXCR3-B are capable of binding the chemokine PF-4 with high affinity, similar to the one of IP-10, while the transfectants of CXCR3-A bind PF-4 with a very low affinity. This is particularly important to note since PF-4, together with IP-10, Mig and l-TAC, is the fourth chemokine having a strong angiostatic and anti tumour effect.
- the receptor capable of mediating its effect was unknown.
- CXCR3- B is the receptor which can mediate the effect of the four angiostatic chemokines on the endothelial cells.
- the chemokines IP-10, Mig, l-TAC and PF-4 activate the same transduction pathways of the signal in the transfectants of CXCR3-B, that is the increase the production of cAMP and of the inhibitor of the cell cycle p21Cip1/waf1 in a way which is p53-independent.
- Rapid Amplification of cDNA ends was performed using oligonucleotides specific for the cDNA portion which is typical of the CXCR3-B alone followed by amplification towards the extremity 5 * and 3'.
- the total RNA was retro-transcripted using a oligo dT16.
- the cDNA was thereafter amplified.
- the probes hybridise specifically to the sample and are cut by the 5'-3'esonuclease activity of Taq polymerase, inducing a higher emission of fluorescence proportional to the quantity of specific PCR product.
- the fluorescence signal was monitored in real time using the 7700 Sequence detector (PE Applied BioSystem, Foster City, CA, USA). donation of the gene seguence of the new receptor in an expression vector and generation of stable transfectants.
- the cells were plated in 96 wells and incubated with various stimuli. At the end of the incubation 1 ⁇ Ci/ml of [ 3 H]-Thymidine are added in the wells and the radioactivity due to the incorporation of the [ 3 H]-Thymidine was analysed with a beta particles counter. Binding
- the binding was performed using 2 x 10 5 transfected endothelial cells.
- the cells were plated and incubated overnight in a standard medium, washed and incubated with a constant concentration (85 pM) of 125 l- labelled chemokines in the presence of increasing concentrations of unlabelled chemokines. After incubation at room temperature for 90 minutes the cells were washed and lysed in NaOH 1N. The radioactivity was determined using a gamma particles counter and the data were analysed with MacLigand software.
- mice Preparation of monoclonal antibodies specific for CXCR3-B BALC/c mice were immunised with a peptide corresponding to the last 51 amino acids of the terminal NH2 portion of CXCR3-B which is selectively expressed by this receptor. After repeated immunisations the mice were sacrificed the spleen was collected and fusion with mielomatose cells was performed in order to obtain the ibridomas. The positivity of the various cloned ibridomas was analysed by ELISA tests on the peptide used for the immunisation. The two selected antibodies were highly specific in recognising the CXCR3-B as demonstrated by the immunohystochemistry test performed on transfectants of CXCR3-A and B and on the mock.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
It is described a novel type of protein exerting therapeutics and diagnostic role in human tumors, its cDNA, alone or in complex with an expression vector.
Description
A PROTEIN THAT MEDIATES ANGIOGENESIS AND TUMOUR GROWTH INHIBITION, ITS CDNA, ALONE OR IN COMPLEX WITH AN EXPRESSION VECTOR
Field of the invention The invention refers to a protein [SEQ. ID. N° 1], its use in diagnosis and therapy of tumours, and its cDNA [SEQ. ID. N° 2]. State of the art
As it is known CXCR3 mediates the angiostatic and anti tumour effects of chemokines IP-10, Mig and l-TAC and it is also known that, depending on the cell type expressing it, it can mediate completely different effects (chemotaxis, proliferation, adhesion, inhibition of proliferation).
In view of the role played by this kind of protein structure for the treatment of various pathologies, in particular tumours, it is evident the importance to identify and make available new proteins capable of controlling the vascular and tumour growth induced by the above said chemokines. Brief description of the drawings
Fig.1 shows the sequence of the protein according to the invention. Fig.2 shows the sequence of the DNA expressing the protein of Fig. 1. Fig.3 shows schematically an expressing vector containing the cDNA sequence coding for CXCR3-B.
Detailed description of the invention
It was now surprisingly found and it is an object of the present application, that a new protein (hereinafter named CXCR3-B) [SEQ: 1] mediates the inhibition of endothelial cell growth induced by angiostatic chemokines IP-10, Mig, l-TAC and PF-4 and probably controls tumour growth.
The present invention is related to the complexes containing the above said protein and the expression vectors and the plasmides containing such complexes. The analysis of the "reading frame" of the gene of the sole chemokine receptor known up to now CXCR3, identified the existence of a possible splicing variant corresponding to a new mRNA.
The existence of this new variant was confirmed by rapid amplification of cDNA ends performed on the total RNA of human thymus and endothelial tissue. The
Northern blotting analysis using a probe for the sequence common to the two variants, permitted to reveal the existence of two bands of mRNA of the expected length; on the contrary using a probe selective for a portion of the sequence of the new variant a new RNA of 1 ,8 kb was identified. Operating as described the expression of the new mRNA of CXCR3 was identified in various human tissues as heart, skeletal muscle, kidney and liver. Thereafter a dosage in quantitative RT-PCR (Taq-Man) was realised, using oligonucleotides selective for the sequences of the two isoforms in various types of human cells. It could be noted that the CXCR3-B is selectively expressed by the human capillary endothelial tissue and by some types of tumour cell of epithelial origin cultivated in vitro. Therefore the CXCR3 expressed by the capillary endothelial tissue which is capable of mediating the endothelial growth inhibition in vitro is not the one known up to now but a distinct variant identified for the first time by the present invention. Using the RT-PCR the total sequence was obtained in the form of cDNA, starting from atg to the stop codon (tga) [SEQ: ID: 2] and it was cloned in an expressing vector of the type usually employed for the transcription of recombinant molecules or for creating transient or stabile transfectants. An expressing vector according to the invention is, for example, a plasmide containing a promoter and a polyadenilation sequence (normally of viral origin) and a resistance to antibiotics for prokaryotes and/or eucaryotes (see Fig. 3).
The correctness of the sequence and its orientation were confirmed by automatic sequencing. Obviously instead of cloning the whole sequence in the expressing vector it is possible to clone a part of it as, for example, it is normally done when probes are to be obtained.
An immortalised cell line of human capillary endothelial cells was transfected with the expressing vector coding for CXCR3-B, an other vector codifying for the known CXCR3 protein (CXCR3-A) and respectively the two vectors deprived of the portion coding for the two proteins. Stable transfectants were obtained by selecting the cells with antibiotics G-418 and hygromicine and in such transfectants the expression of the two types of CXCR3 was examined by using flux cytofluorimetry in the presence of two types of monoclonal antibodies anti-CXCR3. Numerous
clones expressing the two receptor variants were selected, however it was evident that the endothelial cells expressing the new type (CXCR3-B) rapidly died while the clones expressing the known type of CXCR3 (CXCR3-A) all had an high proliferation rate, similar or even superior to the one of the respective "mock. Six of the obtained clones, all expressing low intensity CXCR3-B, could survive some steps, showing a replicative rhythm 4-8 folds lower of the one of the corresponding "mock" and an high trend to precocious cell senescence and death. Other studies, both using the immunofluorescence or the RT-PCR techniques, could confirm that what observed was due to the fact that the cell lines were capable of spontaneously producing under culture high levels of l-TAC, and lower levels of IP-10; which were responsible of the high proliferation of the cells transfected with the known type of CXCR3 (CXCR3-A) and of the growth inhibition of the cells transfected with the new type (CXCR3-B) respectively. In fact an antibody specifically anti-l-TAC was capable of making the transfectants of CXCR3-B to proliferate and to reduce the proliferation of the cells transfected with CXCR3-A. The newly identified receptor (CXCR3-B) is capable of binding all the three chemokines specific for CXCR3 (IP-10, Mig and l-TAC) which can induce inhibition of angiogenesis with various affinity while it can not bind other 17 different and not related chemokines. However, rather surprisingly, the transfectants of CXCR3-B are capable of binding the chemokine PF-4 with high affinity, similar to the one of IP-10, while the transfectants of CXCR3-A bind PF-4 with a very low affinity. This is particularly important to note since PF-4, together with IP-10, Mig and l-TAC, is the fourth chemokine having a strong angiostatic and anti tumour effect. However the receptor capable of mediating its effect was unknown. The data show that CXCR3- B is the receptor which can mediate the effect of the four angiostatic chemokines on the endothelial cells. The chemokines IP-10, Mig, l-TAC and PF-4 activate the same transduction pathways of the signal in the transfectants of CXCR3-B, that is the increase the production of cAMP and of the inhibitor of the cell cycle p21Cip1/waf1 in a way which is p53-independent.
In order to investigate the existence in vivo, of this protein monoclonal antibodies specific for the last 51 amino acids of its terminal NH2 extremity were prepared.
Such antibodies, if used in immunohystochemistry, are capable of recognising the activated endothelial tissue in tumour and inflammations characterised by increased angiogenesis but not in normal tissues. The expression of CXCR3-B is inversely correlated to the tumour extension, to its rate of lymph nodes invasion and to the angiogenesis degree present in the tissue samples of the tumour analysed in 30 patients affected by "non small cell" lung cancer. Experimental part Northern blot analysis 2 μg of poly-A+ RNA were separated on a 2.0% agarose gel containing 0.7 M formaldehyde and ethidium bromide 0.5 mg/ml, the RNA was transferred on a nylon membrane, hybridised with a [α-32P]dCTP labelled cDNA and revealed by autoradiography.
Rapid Amplification of cDNA ends (RACE) Was performed using oligonucleotides specific for the cDNA portion which is typical of the CXCR3-B alone followed by amplification towards the extremity 5* and 3'.
Real-Time Quantitative RT-PCR according to Tag-Man
The total RNA was retro-transcripted using a oligo dT16. The cDNA was thereafter amplified. During the PCR cycles the probes hybridise specifically to the sample and are cut by the 5'-3'esonuclease activity of Taq polymerase, inducing a higher emission of fluorescence proportional to the quantity of specific PCR product. The fluorescence signal was monitored in real time using the 7700 Sequence detector (PE Applied BioSystem, Foster City, CA, USA). donation of the gene seguence of the new receptor in an expression vector and generation of stable transfectants.
The known sequence of CXCR3 and the one of its new variant were cloned in expression vectors and transfected by electroporation in a cell line of endothelial cells immortalised with SV40. Clones of stable transfectants for the two isoforms were thereafter generated using resistance induced to various antibiotics. Incorporation of r3H1-Thvmidine
The cells were plated in 96 wells and incubated with various stimuli. At the end of the incubation 1 μCi/ml of [3H]-Thymidine are added in the wells and the
radioactivity due to the incorporation of the [3H]-Thymidine was analysed with a beta particles counter. Binding
The binding was performed using 2 x 105 transfected endothelial cells. The cells were plated and incubated overnight in a standard medium, washed and incubated with a constant concentration (85 pM) of 125l- labelled chemokines in the presence of increasing concentrations of unlabelled chemokines. After incubation at room temperature for 90 minutes the cells were washed and lysed in NaOH 1N. The radioactivity was determined using a gamma particles counter and the data were analysed with MacLigand software.
Preparation of monoclonal antibodies specific for CXCR3-B BALC/c mice were immunised with a peptide corresponding to the last 51 amino acids of the terminal NH2 portion of CXCR3-B which is selectively expressed by this receptor. After repeated immunisations the mice were sacrificed the spleen was collected and fusion with mielomatose cells was performed in order to obtain the ibridomas. The positivity of the various cloned ibridomas was analysed by ELISA tests on the peptide used for the immunisation. The two selected antibodies were highly specific in recognising the CXCR3-B as demonstrated by the immunohystochemistry test performed on transfectants of CXCR3-A and B and on the mock.
Claims
1. Protein having the amino acids sequence reported in SEQ. ID 1.
2. Portion of cDNA, expressing the protein according to Claim 1, having the nucleotide sequence reported in SEQ ID 2.
3. Complexes consisting of the protein according to claim 1 of CXCR3-B and an expression vector.
4. Complexes consisting of the cDNA sequence according to claim 2 and an expression vector.
5. Complexes according to claims 3 and 4 wherein the expression vectors are those used for the transcription of recombinant molecules or for creating transient or stabile transfectants.
6. Plasmides containing the SEQ ID 1 according to claim 1, or parts thereof, a promoter, a polyadenilation sequence and a resistance to antibiotics for prokaryotes and/or eucaryotes.
7. Plasmides according to claim 6 wherein such polyadenilation sequence is of viral origin.
8. Use of the protein according to claim 1 for the preparation of molecules capable to binding to it.
9. Use of complexes according to claims 3 and 4 as transfectants agents.
10. Use of the plasmides according to claims 6 and 7 as probes.
11. Prokaryotes and/or eucaryote cells transfected with complexes according to claims 3 and 4.
12. Use of the protein according to claim 1 for the preparation of formulations for the indirect treatment of epithelial and vascular tumours , for controlling: angiogenesis, the growth of leukaemia and lymphomas and various hematopoietic tumours, in the transplant rejection acute and chronic and in other cutaneous diseases showing an high angiogenensis, in the chronic inflammatory diseases of the liver (cirrhosis) and kidney (glomerulonephritis, hemolytic-uric syndrome and other vasculopathies) atherosclerosis and vascular alterations, secondary or associated to endothelial damage, miocardio ischaemia.
13. Use of the protein ad diagnostic medium of tumours or diseases expressing a protein according to claim 1.
14. Use of the monoclonal antibodies specific anti-CXCR3-B (clones PLIand PL2) for diagnostic, prognostic analysis and as search reactives.
15. Use of the monoclonal antibodies specific anti-CXCR3-B (clones PL1 and PL2) as pharmacological agents capable of blocking the functions mediated by such receptor CXCR3-B.
16. Complex consisting of a protein according to claim 1 and the chemokine PF-4.
17. Use of the complex according to claim 16 for the synthesis of molecules capable of interacting with the protein according to Claim 1.
18. Use according to claim 17 wherein such molecules have pharmacological action.
19. Use according to claim 17 wherein such molecules have diagnostic action.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003235574A AU2003235574A1 (en) | 2002-01-18 | 2003-01-20 | A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002FI000008A ITFI20020008A1 (en) | 2002-01-18 | 2002-01-18 | PROTEIN CAPABLE OF INHIBITING ANGIOGENESIS AND TUMOR GROWTH, COMPLEXES THAT CONTAIN IT AND CDNA THAT EXPRESSES IT |
| ITFI2002A00008 | 2002-01-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003059949A2 true WO2003059949A2 (en) | 2003-07-24 |
| WO2003059949A3 WO2003059949A3 (en) | 2004-07-22 |
Family
ID=11442311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2003/000116 WO2003059949A2 (en) | 2002-01-18 | 2003-01-20 | A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2003235574A1 (en) |
| IT (1) | ITFI20020008A1 (en) |
| WO (1) | WO2003059949A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210061917A1 (en) * | 2018-02-16 | 2021-03-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and compositions for treating vitiligo |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997025340A1 (en) * | 1996-01-11 | 1997-07-17 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor hsatu68 |
| WO1999050299A1 (en) * | 1998-03-30 | 1999-10-07 | Astrazeneca Ab | Receptors |
-
2002
- 2002-01-18 IT IT2002FI000008A patent/ITFI20020008A1/en unknown
-
2003
- 2003-01-20 AU AU2003235574A patent/AU2003235574A1/en not_active Abandoned
- 2003-01-20 WO PCT/IB2003/000116 patent/WO2003059949A2/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997025340A1 (en) * | 1996-01-11 | 1997-07-17 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor hsatu68 |
| WO1999050299A1 (en) * | 1998-03-30 | 1999-10-07 | Astrazeneca Ab | Receptors |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE EMBL [Online] G protein-coupled receptor CKR-L2, 26 July 1997 (1997-07-26) ZABALLOS A.: "H. sapiens G protein-coupled receptor CKR-L2" Database accession no. Z79783 XP002246738 * |
| LASAGNI LAURA ET AL: "An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 197, no. 11, 2 June 2003 (2003-06-02), pages 1537-1549, XP002246737 ISSN: 0022-1007 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210061917A1 (en) * | 2018-02-16 | 2021-03-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Methods and compositions for treating vitiligo |
Also Published As
| Publication number | Publication date |
|---|---|
| ITFI20020008A1 (en) | 2003-07-18 |
| WO2003059949A3 (en) | 2004-07-22 |
| AU2003235574A8 (en) | 2003-07-30 |
| AU2003235574A1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hieshima et al. | A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. | |
| Pardigol et al. | HCC-2, a human chemokine: gene structure, expression pattern, and biological activity | |
| Hromas et al. | Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells | |
| Ney et al. | Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner | |
| Fujita et al. | Isolation of cDNA clone encoding rat senescence marker protein-30 (SMP30) and its tissue distribution | |
| RU2177480C2 (en) | Polypeptide, method of producing (variants), dna (variants), vector (variants), cell, polypeptide using, pharmaceutical composition (variants) | |
| Govoni et al. | Genomic structure, promoter sequence, and induction of expression of the mouse Nramp1 gene in macrophages | |
| US5985598A (en) | TCL-1 gene and protein and related methods and compositions | |
| EP0320806A2 (en) | T-cell activation related gene | |
| US5824551A (en) | Method for modulating cell apoptosis | |
| Kikuchi et al. | Structure of the murine secretory leukoprotease inhibitor (Slpi) gene and chromosomal localization of the human and murine SLPI genes | |
| WO2003059949A2 (en) | A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector | |
| WO2001023560A2 (en) | Isolated peptides which bind to mhc class ii molecules, and uses thereof | |
| EP0962530A2 (en) | Gene sequence encoding for the angiopoietin related protein scarface 1 | |
| AU741330B2 (en) | Rat ST38.2 chemokine | |
| AU719934B2 (en) | Method for determining expression of aberrant forms of APC protein | |
| US6368790B1 (en) | cDNA encoding P2P proteins and use of P2P cDNA derived antibodies and antisense reagents in determining the proliferative potential of normal, abnormal, and cancer cells in animals and humans | |
| WO1999062956A1 (en) | Angiopoietin related gene sequence scarface 3 | |
| WO2001075123A1 (en) | Novel polypeptide--- a human hepatic nuclear factor 12 and polynucleotide encoding it | |
| JP2002505076A (en) | CDNA encoding C6β-chemokine leukotactin-1 (Lkn-1) isolated from human | |
| EP0850319A1 (en) | Method for modulating cell apoptosis | |
| WO2002000828A2 (en) | A novel polypeptide, a zinc-finger protein 34 and the polynucleotide encoding the polypeptide | |
| WO2000005241A1 (en) | Angiopoietin related gene sequence scarface 2 | |
| WO2001083538A1 (en) | A novel polypeptide, a human k-ras gene protein 36 and the polynucleotide | |
| WO2001046433A1 (en) | A novel polypeptide, aldehyde/ketone reductase 9 and the polynucleotide encoding the polypeptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |